IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v112y2013i3p202-208.html
   My bibliography  Save this article

Applying rapid ‘de-facto’ HTA in resource-limited settings: Experience from Romania

Author

Listed:
  • Lopert, Ruth
  • Ruiz, Francis
  • Chalkidou, Kalipso

Abstract

In attempting to constrain healthcare expenditure growth, health technology assessment (HTA) can enable policy-makers to look beyond budget impact and facilitate more rational decision-making. However lack of technical capacity and poor governance can limit use in some countries. Undertaking de facto HTA by adapting decisions taken in countries with established processes is a method that may be applied while building domestic HTA capacity. We explored the potential for applying this approach in Romania.

Suggested Citation

  • Lopert, Ruth & Ruiz, Francis & Chalkidou, Kalipso, 2013. "Applying rapid ‘de-facto’ HTA in resource-limited settings: Experience from Romania," Health Policy, Elsevier, vol. 112(3), pages 202-208.
    • Handle: RePEc:eee:hepoli:v:112:y:2013:i:3:p:202-208
    DOI: 10.1016/j.healthpol.2013.07.019
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S016885101300208X
    Download Restriction: Full text for ScienceDirect subscribers only
    File URL: https://libkey.io/10.1016/j.healthpol.2013.07.019?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Oortwijn, Wija & Mathijssen, Judith & Banta, David, 2010. "The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries," Health Policy, Elsevier, vol. 95(2-3), pages 174-184, May.
    2. Rob Anderson, 2010. "Systematic reviews of economic evaluations: utility or futility?," Health Economics, John Wiley & Sons, Ltd., vol. 19(3), pages 350-364, March.
    3. Mark Sculpher & Karl Claxton, 2012. "Real Economics Needs to Reflect Real Decisions," PharmacoEconomics, Springer, vol. 30(2), pages 133-136, February.
    4. Costa-i-Font, Joan & Kanavos, Panos, 2007. "Medicines in parallel trade in the European Union: a gravity specification," LSE Research Online Documents on Economics 28787, London School of Economics and Political Science, LSE Library.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Vogler, Sabine & Zimmermann, Nina & de Joncheere, Kees, 2016. "Policy interventions related to medicines: Survey of measures taken in European countries during 2010–2015," Health Policy, Elsevier, vol. 120(12), pages 1363-1377.
    2. Zoltán Kaló & Adrian Gheorghe & Mirjana Huic & Marcell Csanádi & Finn Boerlum Kristensen, 2016. "HTA Implementation Roadmap in Central and Eastern European Countries," Health Economics, John Wiley & Sons, Ltd., vol. 25(S1), pages 179-192, February.
    3. Marian Sorin Paveliu & Elena Olariu & Raluca Caplescu & Yemi Oluboyede & Ileana-Gabriela Niculescu-Aron & Simona Ernu & Luke Vale, 2021. "Estimating an EQ-5D-3L Value Set for Romania Using Time Trade-Off," IJERPH, MDPI, vol. 18(14), pages 1-16, July.
    4. László Gulácsi & Fanni Rencz & Márta Péntek & Valentin Brodszky & Ruth Lopert & Noémi Hevér & Petra Baji, 2014. "Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 27-34, May.
    5. László Gulácsi & Alexandru Rotar & Maciej Niewada & Olga Löblová & Fanni Rencz & Guenka Petrova & Imre Boncz & Niek Klazinga, 2014. "Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 13-25, May.
    6. Elena Olariu & Wael Mohammed & Yemi Oluboyede & Raluca Caplescu & Ileana Gabriela Niculescu-Aron & Marian Sorin Paveliu & Luke Vale, 2023. "EQ-5D-5L: a value set for Romania," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(3), pages 399-412, April.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Sanjib Saha & Ulf-G Gerdtham & Pia Johansson, 2010. "Economic Evaluation of Lifestyle Interventions for Preventing Diabetes and Cardiovascular Diseases," IJERPH, MDPI, vol. 7(8), pages 1-46, August.
    2. Matt Wilkinson-Stokes & Michelle Tew & Celene Y. L. Yap & Di Crellin & Marie Gerdtz, 2024. "The Economic Impact of Community Paramedics Within Emergency Medical Services: A Systematic Review," Applied Health Economics and Health Policy, Springer, vol. 22(5), pages 665-684, September.
    3. Garattini, Livio & van de Vooren, Katelijne & Curto, Alessandro, 2015. "Cost-effectiveness of trastuzumab in metastatic breast cancer: Mainly a matter of price in the EU?," Health Policy, Elsevier, vol. 119(2), pages 212-216.
    4. Dirk Steijger & Chandrima Chatterjee & Wim Groot & Milena Pavlova, 2022. "Challenges and Limitations in Distributional Cost-Effectiveness Analysis: A Systematic Literature Review," IJERPH, MDPI, vol. 20(1), pages 1-14, December.
    5. P. Watson & L. Preston & H. Squires & J. Chilcott & A. Brennan, 2014. "Modelling the Economics of Type 2 Diabetes Mellitus Prevention: A Literature Review of Methods," Applied Health Economics and Health Policy, Springer, vol. 12(3), pages 239-253, June.
    6. Nadia Pillai & Mark Dusheiko & Bernard Burnand & Valérie Pittet, 2017. "A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease," PLOS ONE, Public Library of Science, vol. 12(10), pages 1-22, October.
    7. Lianne Barnieh & Fiona Clement & Anthony Harris & Marja Blom & Cam Donaldson & Scott Klarenbach & Don Husereau & Diane Lorenzetti & Braden Manns, 2014. "A Systematic Review of Cost-Sharing Strategies Used within Publicly-Funded Drug Plans in Member Countries of the Organisation for Economic Co-Operation and Development," PLOS ONE, Public Library of Science, vol. 9(3), pages 1-10, March.
    8. Tim Mathes & Maren Walgenbach & Sunya-Lee Antoine & Dawid Pieper & Michaela Eikermann, 2014. "Methods for Systematic Reviews of Health Economic Evaluations," Medical Decision Making, , vol. 34(7), pages 826-840, October.
    9. Vogler, Sabine & Zimmermann, Nina & de Joncheere, Kees, 2016. "Policy interventions related to medicines: Survey of measures taken in European countries during 2010–2015," Health Policy, Elsevier, vol. 120(12), pages 1363-1377.
    10. Edward Burn & Alexander D. Liddle & Thomas W. Hamilton & Sunil Pai & Hemant G. Pandit & David W. Murray & Rafael Pinedo-Villanueva, 2017. "Choosing Between Unicompartmental and Total Knee Replacement: What Can Economic Evaluations Tell Us? A Systematic Review," PharmacoEconomics - Open, Springer, vol. 1(4), pages 241-253, December.
    11. Francesco Ramponi & Simon Walker & Susan Griffin & Steve Parrott & Colin Drummond & Paolo Deluca & Simon Coulton & Mona Kanaan & Gerry Richardson, 2021. "Cost‐effectiveness analysis of public health interventions with impacts on health and criminal justice: An applied cross‐sectoral analysis of an alcohol misuse intervention," Health Economics, John Wiley & Sons, Ltd., vol. 30(5), pages 972-988, May.
    12. Katelijne Vooren & Alessandro Curto & Livio Garattini, 2015. "Pricing of forthcoming therapies for hepatitis C in Europe: beyond cost-effectiveness?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(4), pages 341-345, May.
    13. Zaheer-Ud-Din Babar & Shane Scahill, 2011. "The Authors’ Reply," PharmacoEconomics, Springer, vol. 29(1), pages 84-86, January.
    14. Elisabet Jacobsen & Dwayne Boyers & Alison Avenell, 2020. "Challenges of Systematic Reviews of Economic Evaluations: A Review of Recent Reviews and an Obesity Case Study," PharmacoEconomics, Springer, vol. 38(3), pages 259-267, March.
    15. Kalle Hirvonen, 2020. "This is US: Geography of evidence in top health economics journals," Health Economics, John Wiley & Sons, Ltd., vol. 29(10), pages 1316-1323, October.
    16. Claudine Bommer & Judith Lupatsch & Nicole Bürki & Matthias Schwenkglenks, 2022. "Cost–utility analysis of risk-reducing strategies to prevent breast and ovarian cancer in BRCA-mutation carriers in Switzerland," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(5), pages 807-821, July.
    17. Pragyan Monalisa Sahoo & Himanshu Sekhar Rout & Mihajlo Jakovljevic, 2023. "Dynamics of Health Financing among the BRICS: A Literature Review," Sustainability, MDPI, vol. 15(16), pages 1-21, August.
    18. Rajan Sharma & Yuanyuan Gu & Teresa Y. C. Ching & Vivienne Marnane & Bonny Parkinson, 2019. "Economic Evaluations of Childhood Hearing Loss Screening Programmes: A Systematic Review and Critique," Applied Health Economics and Health Policy, Springer, vol. 17(3), pages 331-357, June.
    19. Chen Min & Mi Xue & Fei Haotian & Li Jialian & Zhang Lingli, 2021. "An overview of the characteristics and quality assessment criteria in systematic review of pharmacoeconomics," PLOS ONE, Public Library of Science, vol. 16(2), pages 1-13, February.
    20. Mathilda Bongers & Veerle Coupé & Elise Jansma & Egbert Smit & Carin Groot, 2012. "Cost Effectiveness of Treatment with New Agents in Advanced Non-Small-Cell Lung Cancer," PharmacoEconomics, Springer, vol. 30(1), pages 17-34, January.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:112:y:2013:i:3:p:202-208. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.